493 related articles for article (PubMed ID: 23150709)
1. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.
Behringer K; Mueller H; Goergen H; Thielen I; Eibl AD; Stumpf V; Wessels C; Wiehlpütz M; Rosenbrock J; Halbsguth T; Reiners KS; Schober T; Renno JH; von Wolff M; van der Ven K; Kuehr M; Fuchs M; Diehl V; Engert A; Borchmann P
J Clin Oncol; 2013 Jan; 31(2):231-9. PubMed ID: 23150709
[TBL] [Abstract][Full Text] [Related]
2. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial.
Behringer K; Thielen I; Mueller H; Goergen H; Eibl AD; Rosenbrock J; Halbsguth T; Eichenauer DA; Fuchs M; Reiners KS; Renno JH; van der Ven K; Kuehr M; von Wolff M; Diehl V; Engert A; Borchmann P
Ann Oncol; 2012 Jul; 23(7):1818-25. PubMed ID: 22228451
[TBL] [Abstract][Full Text] [Related]
3. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
[TBL] [Abstract][Full Text] [Related]
4. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.
Sieniawski M; Reineke T; Josting A; Nogova L; Behringer K; Halbsguth T; Fuchs M; Diehl V; Engert A
Ann Oncol; 2008 Oct; 19(10):1795-801. PubMed ID: 18544558
[TBL] [Abstract][Full Text] [Related]
5. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.
Haverkamp H; Böll B; Eichenauer DA; Sasse S; Fuchs M; Borchmann P; Diehl V; Engert A; von Tresckow B
J Clin Oncol; 2015 Aug; 33(22):2430-6. PubMed ID: 26101245
[TBL] [Abstract][Full Text] [Related]
6. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
7. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
[TBL] [Abstract][Full Text] [Related]
8. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
9. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD).
Giuseppe L; Attilio G; Edoardo DN; Loredana G; Cristina L; Vincenzo L
Hematology; 2007 Apr; 12(2):141-7. PubMed ID: 17454195
[TBL] [Abstract][Full Text] [Related]
10. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
[TBL] [Abstract][Full Text] [Related]
11. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
Borchmann P; Haverkamp H; Diehl V; Cerny T; Markova J; Ho AD; Eich HT; Mueller-Hermelink HK; Kanz L; Greil R; Rank A; Paulus U; Smardova L; Huber C; Dörken B; Nerl C; Krause SW; Mueller RP; Fuchs M; Engert A
J Clin Oncol; 2011 Nov; 29(32):4234-42. PubMed ID: 21990399
[TBL] [Abstract][Full Text] [Related]
12. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
13. Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood.
van Beek RD; Smit M; van den Heuvel-Eibrink MM; de Jong FH; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Weber RF; Pieters R; de Muinck Keizer-Schrama SM
Hum Reprod; 2007 Dec; 22(12):3215-22. PubMed ID: 17981817
[TBL] [Abstract][Full Text] [Related]
14. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
[TBL] [Abstract][Full Text] [Related]
15. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
16. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
[TBL] [Abstract][Full Text] [Related]
17. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
Tarasenkova AA; Filatova LV; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2012; 58(1):101-9. PubMed ID: 22629838
[TBL] [Abstract][Full Text] [Related]
18. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
Engert A; Josting A; Haverkamp H; Villalobos M; Lohri A; Sökler M; Zijlstra J; Sturm I; Topp MS; Rank A; Zenz T; Vogelhuber M; Nogova L; Borchmann P; Fuchs M; Flechtner HH; Diehl V
J Clin Oncol; 2010 May; 28(13):2239-45. PubMed ID: 20368566
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of advanced Hodgkin lymphoma].
Kreissl S; Borchmann P
Dtsch Med Wochenschr; 2013 Jun; 138(23):1212-4. PubMed ID: 23720173
[No Abstract] [Full Text] [Related]
20. Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy.
Castelo-Branco C; Nomdedeu B; Camus A; Mercadal S; Martínez de Osaba MJ; Balasch J
Fertil Steril; 2007 Mar; 87(3):702-5. PubMed ID: 17173900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
